Objectives: Chronic heart failure (CHF) has been associated with an increased risk of poorer cognitive performance in older adults. Reversibility of cognitive impairment after medical treatment has been reported, although the restorative effects of enhanced external counterpulsation (EECP) on cognitive performance have not been studied. We investigated the effect of EECP on cognitive functions in CHF patients.
D
espite improvements in medical therapies, chronic heart failure (CHF) is one of the most common cardiovascular disorders and is associated with high morbidity and mortality. [1] Cognitive impairment is prevalent in CHF patients, [2] [3] [4] [5] with up to approximately 80% of CHF patients having some form of cognitive impairment. [4] Deficits in attention, executive function and memory are common in heart failure patients. [4, 5] For example, executive function is a commonly impaired domain and encompasses the brain functions that allow individuals to process information and make decisions related to managing novel situations. Impairments in executive function cause decreases in functional status and self-management ability. [6, 7] When CHF patients have worsening symptoms, intact executive function supports accurate processing of the worsening symptoms and concludes that contacts with health care providers are necessary.
In patients with CHF, it is important to teach patients self-care behaviors for preventing fatal events. [8] Impairments in cognitive functions probably contribute to a reduced capacity to understand and comply with treatment regimens, resulting in a worse prognosis. [4] There are many pathophysiological factors that have been demonstrated to influence the degree of cognitive impairment in CHF, including structural brain pathology, decreased cerebral blood flow, and dysfunction of the autonomic nervous system (ANS). [9, 10] CHF patients may have many brain abnormalities on neuroimaging studies, such as cerebral atrophy and infarcts, [11, 12] white matter hyperintensities, [13, 14] and alterations in cerebral metabolism. [15] Such abnormalities have been strongly associated with cognitive impairment in persons with cardiovascular disease. [16] CHF patients also have reduced cerebral perfusion compared with healthy controls. Decreased cerebral perfusion contributes to cognitive impairment and may be caused by multiple factors. [9] Despite optimal medical treatments and new revascularization techniques, a significant number of CHF patients have many difficulties in their daily life. Enhanced external counter pulsation (EECP) is a non-pharmacological and non-invasive treatment, administered in an outpatient setting. A course of EECP treatment typically involves 35 one-hour sessions, usually five days a week over a seven-week period. Numerous clinical trials have shown that EECP is safe and effective in patients with ischemic heart disease, with or without left ventricular dysfunction, improving their quality of life. EECP appears to be beneficial as an adjunctive therapy in heart failure patients of any etiology. [17] [18] [19] [20] The present study examines the possibility that cognitive function may be modifiable by EECP treatment by assessing cognitive function over a seven-week period in CHF patients. Evidence of global cognitive improvement was shown in CHF patients under medical care, with such improvement indicating the possibility that the cognitive dysfunction observed in this population might be modifiable. Exploratory analyses were conducted to identify possible mechanisms for cognitive changes.
PATIENTS AND METHODS

Study population
Thirty-six CHF patients (mean age: 66±10 years) with a diagnosis of ischemic cardiomyopathy and CHF between January 2008 and August 2010, who were New York Heart Association (NYHA) Class II-IV and Canadian Cardiovascular Society (CCS) Class II-IV, were enrolled in this study. The subjects were selected in a consecutive fashion. All patients were referred for EECP therapy by the same cardiologist who had been specially trained in this treatment. After explanations, some patients who lived far from the hospital and reported feeling fine declined the EECP therapy. Those patients declining treatment served as the control group. All patients signed a consent form.
While 18 patients constituted the EECP treatment arm, 18 patients who declined EECP treatment served as a control group though they remained on the medical therapy. One patient in the treatment group could not finish his 35-hour EECP program. One patient underwent dialysis due to progression of his chronic renal disease. One patient withdrew his informed consent to participate in the study. One patient declined the second evaluation for cognitive function when the EECP treatment was completed. Exclusion criteria were as follows: patients who had abdominal aortic aneurysm requiring surgical repair, stent-repaired abdominal aortic aneurysm, severe peripheral artery disease, active deep venous thrombosis, significant coagulopathy, severe aortic insufficiency, severe hypertension (≥180/100 mmHg), severe pulmonary hypertension, and decompensated CHF.
The study was conducted in accordance with the Declaration of Helsinki and was approved by our local institutional ethics committee. All patients gave informed consent before entering the study.
EECP treatment protocol
Patients assigned to EECP received 35 1-hour sessions over seven weeks. Three pneumatic cuffs were placed around the lower limbs and buttocks and were inflated sequentially upward at the onset of diastole, and released rapidly and simultaneously before the onset of systole. The protocol-specified applied pressure was at least 280 mmHg and was reached within 5 minutes of the initiation of treatment. Pulse oximeter was monitored continuously during the treatment session, and the subject's clinical status was re-evaluated if the oxygen saturation dropped by ≥4%.
Cognitive measurements
Patients and controls underwent neuropsychological tests, evaluating a wide range of cognitive domains including attention, short-and long-term memory, verbal memory, and executive and visuospatial functions. All tests were applied to both groups by the same blinded neuropsychologist before and after EECP sessions, and the tests were repeated after the 7th-8th week of entering the study. The total score of the 10 recall tests was named as short-term memory. After about 40 minutes, patients were asked to repeat the 15 words to evaluate how many of them they remembered. This is referred to as delayed re-call test. If the person is unable to remember these words, a forced-choice checklist is used in which phonemic and semantic clues are included, in order to assist the patient in selecting the correct words (Oktem, 1992). To measure the language domain, the Boston Naming Test was administered.
Verbal fluency was measured by asking the participant to list as many words as possible beginning with the letters K, A, and S and animal names in one minute. Executive functions were assessed with Verbal Fluency Test, Stroop Test, Clock-Drawing Test, and WAIS-R Similarities Subtest. To measure working memory, WAIS and Digit Span Subtests were administered. In the Forward Digit Span Test, patients are asked to recall a series of digits in the same order, while on the backward digit span test, they are asked to recall a series of digits in reverse order. Visuospatial skills were evaluated with Benton Face Recognition Test and Figure Coping Test (Table 1) .
Echocardiographic assessment
All participants underwent transthoracic echocardiography by means of an echocardiograph equipped with a broadband transducer (Vivid 7 ® , GE VingMed UltrasoundAS; Horten, Norway). Measurements of the left atrium, LV, and right ventricle (RV) were obtained from the parasternal long-axis and apical four-chamber views, in accordance with standard criteria. Left ventricular ejection fraction (LVEF) was calculated 24 hours after hospitalization. The normal value for the Triage ® BNP test was <100 pg/ml.
Statistical Methods
The Statistical Package for the Social Sciences (SPSS) 13.0 was used for statistical analyses of the study. Results are presented as mean±SD or as percentages and numbers for categorical data. In comparing the results between the EECP and control groups of the study, continuous variables that were normally distributed were analyzed with two-tailed t test and unequally distributed variables were analyzed with Mann-Whitney U-test. Categorical data and proporusing the modified Simpson rule in the apical twoand four-chamber views. Mitral flow was measured from the apical four-chamber view with pulsed-wave Doppler, by placing the sample volume at the tips of the mitral leaflets.
Blood samples
Each patient had fasting blood samples drawn from a large antecubital vein for the determination of brain natriuretic peptide (BNP) values before entering the study and after the 7-8-week study period. The BNP levels were analyzed by means of the Triage ® BNP test (Biosite Incorporated; San Diego, CA, USA) within tions were analyzed using chi-square. A p value <0.05 was considered significant.
RESULTS
The characteristics of the study participants are listed in Table 2 . Both groups had similar baseline characteristics. Fourteen patients in the EECP arm and 18 patients in the control group completed the study. After the treatment period, improvement in NYHA functional classification (2.4±0.6 vs. 1.5±0.5, p<0.001) and CCS functional classification of angina (1.9±0.6 vs. 1.1±0.5, p<0.001) was observed in patients with EECP treatment. LVEF increased from 32±12% to 36±14% (p=0.028), and BNP levels decreased from 826±892 pg/ml to 589±861 pg/ml in patients with EECP treatment (p=0.048) ( Table 3) . treatment score: 8.3±4.4; p=0.020) ( Table 4) .
Results of memory tests
Results of attention tests
In the EECP group, there was a significant improvement in the forward row score of the attention subtest of WMS, namely digit span forward, compared to their pretreatment scores (basal score: 4.5±0.1, post-treatment score: 5.1±1.2; p=0.020). Changes in the digit span backward part of the same test were not significant (basal score: 2.6±1.1, post-treatment score: 3.3±0.7; p=0.058). The attention subtests of WMS did not differ after the treatment period in the medical treatment group (Table 4) . 
Results of executive function tests
Results of visuospatial functions
After treatment, Figure Copy Subtest of visuospatial function in the control group was significantly increased (basal score: 8.2±4.9, post-treatment score: 11.6±4.2; p=0.028) ( Table 4 ). In the EECP group, visuospatial function score was not changed after treatment compared to before treatment.
DISCUSSION
Although CHF patients had better NYHA functional class, angina class, increased LVEF, and decreased BNP levels after treatment compared to before treatment, the control group did not show similar improvements in those parameters. CHF patients showed an improvement in memory, attention and executive functions of cognition after EECP therapy. The tests evaluated all domains especially executive functions of cognition. The greatest improvement was seen in the total score of the Boston Naming improvement in Figure Copy Tests, meaning that visuospatial function domains improved. The mechanisms related to cognitive improvement in the parieto-occipital region might be similar to those of other regions in which improvement in cognitive functions are observed. We found that short-term memory scores of the WMS-R Story-Memory Test were decreased, while long-term memory scores of the WMS-R Story-Memory Test did not change in the EECP group when scores before and after the EECP procedure were compared. In contrast, in the medical treatment group, short-term memory scores of the WMS-R Story-Memory Test did not change, while long-term memory scores were lower after the treatment period. The reason for the lower short-term memory scores in the EECP group can be related to the functional organization of the short-term memory. Since executive functions are associated with the frontal region, short-term memory is related with associative areas of the brain. [22] In several studies, it has been reported that CHF patients have poorer performance compared with healthy participants in memory and executive functions. [4, 23] The etiopathogenesis of cognitive impairment in heart failure remains largely unknown. The chief etiological hypotheses are intermittent cerebral hypoperfusion and autonomic dysregulation. Evidence for chronic hypoperfusion due to CHF had been published in the literature. [24] Mainly cerebral hypoperfusion and autonomic dysregulation occur in heart failure patients and lead to changes in grey and white matter areas of the brain, which results in cognitive impairment.
End-stage heart failure can cause global brain ischemia concluding in cognitive deficits, which may not be noticeable by the clinician as a neurological deficit but can similarly disrupt the life of the patient. Since current literature reports that approximately 25-80% of individuals with heart failure have impairment in one or more cognitive domains, cognitive impairment in heart failure patients is important because of poor self management and frequent hospitalizations. [4] The most frequently affected cognitive domain is executive function, which allows individuals to process information and make decisions. Impairments in executive function cause decreases in functional status [6] and lead to poor daily living activities due to decisionmaking inability. [7] In our study, after EECP treatment, mild improvement in executive functions can be the goal factor that increases functional status and improves daily living activities of the CHF patient.
Results of the randomized controlled Prospective Evaluation of EECP in Congestive Heart failure (PEECH) trial showed significant improvement in NYHA functional classification in CHF patients with EECP. [19] In previous studies, it was shown that EECP treatment improves angina in patients with or without systolic heart failure. [25] [26] [27] [28] In one study, EECP therapy improved both global LV systolic and diastolic functions in patients with chronic angina pectoris. A significant increase in LVEF was shown with EECP treatment in the above-mentioned study. [29] In the present study, EECP treatment improved patients' NYHA class, CCS class and LVEF. BNP levels were reduced significantly in the EECP group in our study. Patients without EECP treatment had no statistically significant improvement in NYHA class, CCS class, LVEF, or BNP level at the end of the treatment. It was shown that impaired cardiac function can adversely affect the brain via decreased perfusion. Adjusted global cognitive performance, as well as performance in visuoconstruction and motor speed, was significantly directly associated with LVEF. Patients with low EF had worse cognitive performance, in particular in global and motor speed cognitive scores. Decreased EF may exacerbate cerebral hypoperfusion. [30] It was shown in this study that patients with EECP treatment had higher LVEF and decreased BNP levels, which are signs of better heart function. Levenson et al. [31] reported that EECP therapy reduces carotid arterial stiffness and resistance in patients with stable coronary artery disease and augments carotid blood flow and concomitantly reduces the regional vascular resistance.
In our study, the EECP treatment group also had better cognition after the treatment period. We assumed that the treatment with EECP improved heart functions, which may increase the brain perfusion in grey and white matter, which results in better cognitive functions. Patients in the control group had neither better LVEFs nor lower BNP levels after seven weeks. These recovery differences between the EECP group and control group seemed to support our theory of why EECP and medical treatment had better effects on the executive function of cognition compared to medical treatment alone in ischemic heart failure.
The effect of treatment with EECP on exercise hemodynamics and myocardial stress perfusion in patients with chronic stable angina has been studied. A majority of patients had improved exercise tolerance after EECP treatment, and a similar percentage of patients had improved radionuclide stress perfusion images. Post-EECP, maximal exercise heart rate and blood pressure, while demonstrating a linear relation with exercise duration, did not increase significantly despite the increased exercise duration. This suggests that the increase in exercise duration after treatment with EECP is due to both improved myocardial perfusion and altered exercise hemodynamics. EECP therapy thus appears to exert a "training" effect, decreasing peripheral vascular resistance and the heart rate response to exercise. [32] Short-term cardiac rehabilitation such as four weeks of exercise reduced BNP, independent of LVEF, and improved physical fitness. A decreased level of BNP was inversely related to maximal performance and VO 2 max. [33] Exercises may improve physical functioning among generally healthy older adults, [34] and some exercises helped to improve cognitive functions in the healthy and nonhealthy groups. [34] [35] [36] [37] We determined that patients with EECP treatment had decreased BNP levels, which may be a sign of better physical performance and better VO2 max levels for this patient group in daily life. It seems that the training effect of EECP may help the improvement in cognitive functions, similar to exercise training. This hypothesis may be supported by the fact that patients in the control group demonstrated no such training effects as seen in the EECP group.
It was recently shown that EECP increased brachial and femoral artery flow-mediated dilation and the nitric oxide turnover/production markers nitrate and nitrite and 6-keto-prostaglandin, whereas it decreased endothelin-1 and the nitric oxide synthase inhibitor asymmetrical dimethylarginine. EECP decreased the proinflammatory cytokines tumor necrosis factor-α, monocyte chemo-attractant protein-1, soluble vascular cell adhesion molecule-1, high-sensitivity Creactive protein, and the lipid peroxidation marker 8-isoprostane. The authors concluded that EECP has a beneficial effect on peripheral artery flow-mediated dilation and endothelial-derived vasoactive agents in patients with symptomatic coronary artery disease. [38] A correlation has been found between serum nitric oxide levels and cognitive deterioration in patients with dementia. [39] Improvement in cognitive functions may be a result of some parts of those effects as mentioned above, such as better peripheral artery flow-mediated dilation and increased nitric oxide level in patients with ischemic cardiomyopathy who were treated with EECP. Those effects that were above the nitric oxide level, such as improved radionuclide stress perfusion and increased nitric oxide levels, might explain why patients receiving EECP treatment had improved angina symptoms, while those with medical treatment did not. Most of these factors that were discussed above, such as improvement in exercise capacity, less chest pain in daily life and increase in EF, may play a very important role in the improvement in cognitive function in patients with EECP.
It seems that better improvement in cardiac functions and functional status of patients with EECP compared to the control group may be the main reasons for their better recovery in the domains of cognition. Unfortunately, to the best of our knowledge, the effects of EECP on cognition have not been reported to date. To our knowledge, this is the first study to examine the influence of EECP on cognitive deficits in a carefully characterized and diverse sample of heart failure patients. In the current study, we found significant improvement in cognitive functions especially in the executive functions of ischemic heart failure patients. Improvement in executive functions may cause enhancement in daily living activities and quality of life of CHF patients.
Limitations
The results of this study are limited by the small sample size of the participants, and thus limit our ability to generalize the results. The reasons for the small size were 1. EECP treatment is a very long treatment option and takes time, and 2. Administration of the cognitive tests is very time-consuming. Future studies with larger sample sizes are needed to confirm the effects of EECP on cognition.
In conclusion, cognitive deficits represent a common problem that affects patients with systolic heart failure. A number of tests have been used to measure cognitive function in heart failure. [3, 5, 6, [40] [41] [42] Memory deficits are most common, followed by a psychomotor slowing and decreased executive function. In this study, we utilized memory, working memory, language, attention, executive functions, and visuospatial functions tests, and examined all six of the cognitive domains most often impaired in heart failure (i.e., attention, working memory, long-term memory, learning, executive function). [6] In the present study, patients with systolic heart failure showed an improvement in memory, visuospatial, executive, and attention domains as an improvement in LVEF, BNP levels, functional class, and angina class. We conclude that EECP and medical treatment together demonstrated better effects on cognitive functions than medical treatment alone, but also in daily living activities and functional income in patients. It seems that EECP and medical treatment together could be a new treatment option to improve cognitive function in patients with systolic heart failure.
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